Abstract
BackgroundLysosome-associated protein transmembrane 4b-35 (LAPTM4B-35) is a member of the mammalian 4-tetratransmembrane spanning protein superfamily, which is overexpressed in several solid malignancies. However, the expression of LAPTM4B-35 and its role in the progression of prostate cancer (PCa) is unknown. The aim of the present study was to investigate the LAPTM4B-35 expression in PCa and its potential relevance to clinicopathological variables and prognosis.MethodsImmunohistochemistry was used to determine the expression of LAPTM4B-35 protein in 180 PCa tissues in comparison with 180 normal benign prostatic hyperplasia (BPH) specimens. The correlation between the expression of the LAPTM4B-35 protein and the clinicopathologic characteristics of patients with PCa was analyzed.ResultsStatistical analysis showed that LAPTM4B-35 expression was significantly elevated in PCa compared with the BPH controls. High LAPTM4B-35 staining was present in 71.11% of all the cases with PCa. The overexpression of LAPTM4B-35 was significantly associated with the lymph node metastasis, seminal vesicle invasion, PCa stage, higher Gleason score, higher preoperative PSA, and biochemical recurrence (BCR). The Kaplan-Meier survival analysis showed that the high expression of LAPTM4B-35 was related to the poor overall survival and BCR-free survival of patients with PCa. Multivariate Cox analysis showed that LAPTM4B-35 was an independent prognostic factor for both overall survival and BCR-free survival of patients with PCa.ConclusionsOverexpression of LAPTM4B-35 may be associated with tumor progression and poor prognosis in PCa and thus may serve as a new molecular marker to predict the prognosis of PCa patients.
Highlights
As the most common malignant neoplasm in men, prostate cancer (PCa) is the second most common cause of tumor related deaths in the United States [1]
LAPTM4B-35 protein is overexpressed in PCa tissues LAPTM4B-35 expression was overexpressed in PCa cases compared with benign prostatic hyperplasia (BPH), and the difference was statistically significant (P,0.001) (Table 1)
LAPTM4B-35 expression was significantly higher in the higher PCa stage and seminal vesicle invasion cases; LAPTM4B-35 expression was significantly increased in PCa patients with lymph node metastasis, higher preoperative PSA, higher Gleason score, and biochemical recurrence (BCR)
Summary
As the most common malignant neoplasm in men, prostate cancer (PCa) is the second most common cause of tumor related deaths in the United States [1]. Efforts to identify more molecular markers that could be used to detect PCa as well as individualize both patient prognosis and therapy are of great clinical importance. Conventional prognostic factors such as Gleason score, preoperative PSA levels or ratio of involved biopsies only insufficiently predict patient outcome for currently available therapies. The identification of novel prostate cancer biomarkers should be of first clinical priority, when taking into consideration the problematic heterogeneity of prostate tumors and the solutions that personalized medicine can provide These biomarkers should be capable of enhancing differential diagnosis and indicating the course of PCa disease as early and as accurate as possible, limiting the amount of non-essential medical procedures [7,8,9,10]. The aim of the present study was to investigate the LAPTM4B-35 expression in PCa and its potential relevance to clinicopathological variables and prognosis
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
